PARIS, August 28 /PRNewswire/ --     The Board of Directors, meeting on 28 August 2007, under the
chairmanship of Albert Saporta approved the consolidated financial statements
at 30 June 2007:

(EUR millions)           2007   % of    2006   % of   % change
                              HY1  sales     HY1  sales   2007/2006

    Sales                    74.8  100.0    64.2  100.0        17
    Cost of sales           (16.9) (22.5)  (14.6) (22.7)       16
    Gross profit             57.9   77.5    49.6   77.3        17
    General,                (31.3) (41.9)  (28.0) (43.6)       12
    administrative and
    selling expenses
    Gross operating profit   26.6   35.6    21.6   33.7        23
    before R&D
    R&D                     (11.2) (15.0)   (9.4) (14.6)       19
    Operating profit         15.4   20.6    12.2   19.1        26
    Net profit (Group        10.1   13.6     7.7   12.0        32
    share)
    Net earnings per share   0.76           0.59               30
    (diluted, in EUR)
    Net borrowings            9.3   (16%)   13.3   (29%)      (30)
    (gearing)



2007 1st half-year registered a marked improvement in
operating profitability

Operating profit (up 26%) fully benefited from the sharp
growth in sublingual route sales (up 21%), a segment in which Stallergenes
consolidated its leadership and strategic positioning. Net profit increased
by 32% to EUR 10.1 million. Net borrowings were down 30%.

International roll-out of operations

The 1st half-year represents a major milestone in the Group's
international development: incorporation of StallergÚnes BV in Holland,
active preparation of the ORALAIR(R) Grasses tablet registration in Canada,
operational rollout in the East of the European Union (Austria, Slovenia and
Romania).

Outlook

The Company remains confident in the registration of ORALAIR
Grasses in Germany at the end of 2007 and in the initialisation of the mutual
recognition procedure in strategic European countries.

2007 2nd half-year growth should remain strong but at a
slightly lower pace than in the 1st half-year. Additional resources dedicated
to the launch of ORALAIR(R) Grasses in Germany and to the financing of the
new plant - operational by end 2007 - should drive profitability and net
borrowings to levels close to those of 2006 in absolute values.

About StallergÚnes

Stallergenes is a European biopharmaceutical company dedicated
to desensitization treatments for the prevention and cure of allergy-related
respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma.

A pioneer and leader in sublingual desensitization treatments,
Stallergenes devotes 15% of its sales to Research and Development and is
today fully involved in the development of a new therapeutic family, the
sublingual desensitization tablets.

With headquarters in France, Stallergenes markets its products
in approximately 40 countries. StallergÚnes realised 2006 sales of EUR 126.5
million, of which half outside France.

StallergÚnes' shares are listed on Eurolist Compartment B of
the Euronext Paris Stock Exchange.

ISIN code: FR0000065674, Reuters code: GEN.PA, Bloomberg code:
GEN.FP

For additional information on StallergÚnes, please visit our
website: http://www.stallergenes.com